CNBX Pharmaceuticals Inc. (CNBX)
OTCMKTS
· Delayed Price · Currency is USD
0.0001
-0.0001 (-50.00%)
Mar 6, 2026, 4:00 PM EST
CNBX Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is September - August.
Millions USD. Fiscal year is Sep - Aug.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Nov '25 Nov 30, 2025 | Aug '25 Aug 31, 2025 | Aug '24 Aug 31, 2024 | Aug '23 Aug 31, 2023 | Aug '22 Aug 31, 2022 | Aug '21 Aug 31, 2021 | 2020 - 2016 |
| Revenue | - | - | 0.13 | 0.41 | 0.03 | - | Upgrade
|
| Revenue Growth (YoY) | - | - | -68.29% | 1269.13% | - | - | Upgrade
|
| Gross Profit | - | - | 0.13 | 0.41 | 0.03 | - | Upgrade
|
| Selling, General & Admin | 0.3 | 0.27 | 0.52 | 0.91 | 1.8 | 0.83 | Upgrade
|
| Research & Development | - | - | 0.19 | 0.43 | 1.18 | 1.77 | Upgrade
|
| Operating Expenses | 0.3 | 0.27 | 0.71 | 1.34 | 2.98 | 2.6 | Upgrade
|
| Operating Income | -0.3 | -0.27 | -0.58 | -0.93 | -2.95 | -2.6 | Upgrade
|
| Interest Expense | -0.09 | -0.04 | -0.02 | -0 | -0 | -0 | Upgrade
|
| Currency Exchange Gain (Loss) | -0 | -0 | -0 | 0 | -0.06 | -0.02 | Upgrade
|
| Other Non Operating Income (Expenses) | - | - | - | -0.05 | -0.72 | -0.96 | Upgrade
|
| EBT Excluding Unusual Items | -0.39 | -0.31 | -0.61 | -0.98 | -3.74 | -3.59 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | - | - | 0.2 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | -0.09 | -2.73 | 0.01 | 0.2 | Upgrade
|
| Pretax Income | -0.39 | -0.31 | -0.7 | -3.71 | -3.72 | -3.19 | Upgrade
|
| Net Income | -0.39 | -0.31 | -0.7 | -3.71 | -3.72 | -3.19 | Upgrade
|
| Net Income to Common | -0.39 | -0.31 | -0.7 | -3.71 | -3.72 | -3.19 | Upgrade
|
| Shares Outstanding (Basic) | 266 | 91 | 30 | 9 | 1 | 1 | Upgrade
|
| Shares Outstanding (Diluted) | 266 | 91 | 30 | 9 | 1 | 1 | Upgrade
|
| Shares Change (YoY) | 755.99% | 199.69% | 242.76% | 621.77% | 5.92% | 2.95% | Upgrade
|
| EPS (Basic) | -0.00 | -0.00 | -0.02 | -0.42 | -3.05 | -2.77 | Upgrade
|
| EPS (Diluted) | -0.00 | -0.00 | -0.02 | -0.42 | -3.05 | -2.77 | Upgrade
|
| Free Cash Flow | -0.18 | -0.17 | -0.25 | -0.11 | -1.68 | -2.49 | Upgrade
|
| Free Cash Flow Per Share | -0.00 | -0.00 | -0.01 | -0.01 | -1.38 | -2.16 | Upgrade
|
| Gross Margin | - | - | 100.00% | 100.00% | 100.00% | - | Upgrade
|
| Operating Margin | - | - | -448.31% | -227.07% | -9860.37% | - | Upgrade
|
| Profit Margin | - | - | -534.46% | -904.57% | -12428.23% | - | Upgrade
|
| Free Cash Flow Margin | - | - | -188.71% | -27.43% | -5610.68% | - | Upgrade
|
| EBITDA | - | -0.2 | -0.51 | -0.77 | -2.76 | -2.38 | Upgrade
|
| EBITDA Margin | - | - | - | -187.56% | - | - | Upgrade
|
| D&A For EBITDA | - | 0.07 | 0.07 | 0.16 | 0.2 | 0.22 | Upgrade
|
| EBIT | -0.3 | -0.27 | -0.58 | -0.93 | -2.95 | -2.6 | Upgrade
|
| EBIT Margin | - | - | - | -227.07% | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.